An interventional study of Attentional Bias Modification Treatment (ABMT) - Active and Attentional Bias Modification Treatment - Placebo in Generalized Anxiety Disorder, Social Anxiety Disorder and Panic Disorder, sponsored by Hospital de Clinicas de Porto Alegre. Status unknown at 2 sites in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-07-21.
Sponsored by Hospital de Clinicas de Porto Alegre · Not applicable, Interventional, and Treatment
The objective of this project is to test the combination of active or placebo Attentional Bias Modification Treatment (ABMT) to usual treatment for anxiety disorder patients resistant to antidepressants.
4,868 studies on the registry are indexed under Anxiety Disorders; 1,390 are open to participants now.
This study's planned enrollment of 60 is below the median of 80 across 4,174 interventional studies indexed under Anxiety Disorders.
Browse Anxiety Disorders studies →Hospital de Clinicas de Porto Alegre is the lead sponsor of 450 studies on the registry; 61 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Treatment as usual (TAU): selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor Attention Bias Modification Treatment (ABMT) - active
Other: Attentional Bias Modification Treatment (ABMT) - Active
Treatment as usual (TAU): selective serotonin reuptake inhibitor or serotonin norepinephrine reuptake inhibitor Attention Bias Modification Treatment (ABMT) - placebo (sham)
Other: Attentional Bias Modification Treatment - Placebo
The ABMT consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the ABM condition, the target appears at the neutral-face location in all angry-neutral trials. Probe type (\< or \>) is not factorially counterbalanced but appears with equal probability for each of the following: angry-face location, probe location, or actor. Number of sessions: 10 ABMT sessions, 5 weeks (2 sessions once a week occurring in the same day with 40 minutes interval)
The Placebo protocol consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the placebo condition, angry-face location, probe location, and actor are fully counterbalanced in presentation. Number of sessions: 10 ABMT sessions, 5 weeks (2 sessions once a week occurring in the same day with 40 minutes interval)
Overall Anxiety Severity and Impairment Scale (OASIS)
Disorder non-specific primary outcome: Score change on OASIS (Overall Anxiety Severity and Impairment Scale) from baseline to endpoint and 3-months follow-up
Time frame: Endpoint and 3-months follow-up
Panic Disorder Severity Scale (PDSS), Generalized Anxiety Disorder 7-item Scale (GAD-7) or Liebowitz Social Anxiety Scale (LSAS)
Disorder-specific primary outcome: For patients with Panic Disorder - change from baseline to endpoint and 3 months follow-up in the PDSS For patients with Generalized Anxiety Disorder - change from baseline to endpoint and 3 months follow-up in the GAD-7 For patients with Social Anxiety Disorder - change from baseline to endpoint and 3 months follow-up in the LSAS
Time frame: Endpoint and 3-months follow up
Beck Depression Inventory (BDI)
Score change on BDI from baseline to endpoint and 3-months follow up
Time frame: Endpoint and 3-months follow-up
Beck Anxiety Inventory (BAI)
Score change on BAI from baseline to endpoint and 3-months follow up
Time frame: Endpoint and 3-months follow-up
DSM-5 Cross-Disorder Dimensional Scale [Brazilian version]
Score change on Cross-D from baseline to endpoint and 3-months follow up
Time frame: Endpoint and 3-months follow-up
Profile of Mood States (POMS)
Score Change on POMS from baseline to endpoint and 3-months follow up.
Time frame: Endpoint and 3-months follow-up
Clinical Global Impression(CGI)
Dichotomous outcome: percentage of patients with a score of 2 or less at the endpoint and 3-months follow-up evaluations
Time frame: Endpoint and 3-months follow-up
Dot-probe and Executive Function Measures
Change in bias in attention orienting and executive function measures from baseline to endpoint and 3-months follow-up
Time frame: Endpoint and 3-months follow-up
This study is status unknown, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital de Clinicas de Porto Alegre